Heel - Cough and Cold

Percentage decrease in viral activity with Engystol®treatment1

Adapted from Oberbaum et al.1

80%

73%

37%

22%

*HSV-1: Herpes Simplex Virus Type 1; **RSV: Respiratory Syncytial Virus; HRV-14: Human Rhinovirus Type 14.

R el

at iv

e %

in h

ib it

io n

Engystol® dilution (1:2)

HSV-1* proteins

Adenovirus 5 proteins

RSV** (viral plaque) infectivity

HRV-14 (viral plaque) infectivity

Inhibition of viral activity was based on viral protein-specific ELISA (Adenovirus 5, HSV-1) and plaque-reduction assay (HRV-14, RSV).

COUGH AND COLD

Mode of action DEMONSTRATED ANTIVIRAL ACTIVITY AGAINST SEVERAL COMMON VIRUSES1,2

References 1) Oberbaum M, Glatthaar-Saalmuller B, Stolt P, Weiser M. Antiviral activity of Engystol: an in vitro analysis.

J Altern Complement Med. 2005; 11(5):855-862. doi:10.1089/acm.2005.11.855 2) Roeska K, Seilheimer B. Antiviral activity of Engystol(R) and Gripp-Heel(R): an in-vitro assessment.

Immune Based Ther Vaccines. 2010;8(1):6. doi:10.1186/1476-8518-8-6 3) Wronski S, Dannenmaier J, Schild S, et al. Engystol reduces onset of experimental respiratory syncytial virus-induced respiratory inflammation in mice by

modulating macrophage phagocytic capacity. PLoS One. 2018;13(4): e0195822. doi:10.1371.journal.pone.0195822 4) Wagner H, Jurcic K, Doenicke A, Behrens N. Influence of Homeopathic Drug Preparations on the Phagocytosis Capabiblity of Granulocytes: In-vitro tests

and controlled single-blind studies. Biol Ther. 1993;11(1):43-49. 5) Enbergs H. Effects of the homeopathic preparation Engystol on interferon-gamma production by human T-lymphocytes.

Immunol Invest. 2006;35(1):19-27. doi:10.1080/08820130500496753

STIMULATES AND SUPPORTS THE IMMUNE SYSTEM IN FIGHTING COLDS2-5

Inflammatory cell count in the lung following RSV* infection and Engystol® treatment3

Adapted from Wronski et al.3

Control (no virus or Engystol®)

Virus, no Engystol®

Virus + Engystol®: 0.4 tablet/kg

Virus + Engystol®: 2.57 tablets/kg

Virus + Engystol®: 5.1 tablets/kg

BALF** absolute cell numbers [x 105] for day 1 post infection are given as mean.

*RSV: Respiratory Syncytial Virus; **BALF: Bronchoalveolar Lavage Fluid.

B A

L F

** d

if fe

re n

ti a l c e ll

c o

u n

t [x

1 0

5 ]

Day 1

Macrophages Neutrophils Lymphocytes

p<0.01

p<0.05

0.8

0.6

0.4

0.2